Positive update on the development of new XF‐platform drug formulations

Collaboration with MedPharm delivers data profiling new XF‐platform drug formulations as potential treatments for dermal and ocular infections

Destiny Pharma, a clinical stage biotechnology company focused on the development of novel, hospital infection prevention treatments that address the global challenge of antimicrobial resistance (AMR), has completed the initial phase of its project with MedPharm to develop new topical formulations of the company’s novel XF‐platform drugs.

Further to forming the collaboration with MedPharm last year, the project has identified a range of new, stable XF formulations with promising drug release profiles and scope for delivery of XF drugs (including clinical stage XF-73, XF-70 and DPD-207 compounds) designed to treat dermal and ocular infections.

These formulations will form the basis of XF drug delivery for Destiny Pharma’s preclinical and clinical programmes and treatments for both acute and chronic infections.

Selected formulations will also be incorporated into ongoing grant-funded projects, including the company’s UK-China AMR, Innovate UK grant-funded collaboration, as announced on 25 January 2019.

Neil Clark, CEO of Destiny Pharma, commented: “We are pleased to announce positive progress made to develop new formulations of XF drugs from our novel antimicrobial XF‐platform. There is an unmet medical need for novel anti-infectives that address dermal and ocular infections with a significantly reduced potential for generating antimicrobial resistance."

"We look forward to continuing to work with MedPharm to support the expansion of our pipeline as we take select formulations into our ongoing preclinical and clinical studies. Our lead drug candidate from the XF-platform, XF‐73 nasal gel, for the prevention of post‐surgical infections, is currently in Phase IIb development with data expected in mid-2020.”

Eugene Ciolfi, CEO of MedPharm, added: “MedPharm’s rigorous development methodology and novel in vitro performance testing capabilities have supported the success of this project. We are delighted to be able to continue our collaboration with Destiny to advance and broaden its product pipeline and address this unmet medical need.”

Companies